Re: “Mortality Attributed to COVID-19 in High-Altitude Populations” by Woolcott and Bergman

Accinelli RA and Leon-Abarca JA . (2020). At high altitude COVID-19 is less frequent: The experience of Peru. Arch Bronconeumol, 56:760–761.

Danser AHJ , Epstein M , and Batlle D . (2020). Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension, 75:1382–1385.

Pun M , Turner R , Strapazzon G , Brugger H , and Swenson ER . (2020). Lower incidence of COVID-19 at high altitude: Facts and confounders. High Alt Med Biol, 21:217–222.

Rivero AC , and Montoya M . (2020). COVID19 en población residente de zonas geográficas a alturas superiores a 2500 msnm (in Spanish). SITUA, 23:19–26.

Woolcott OO , and Bergman RN . (2020). Mortality attributed to COVID-19 in high-altitude populations. High Alt Med Biol, 21:409–416.

Zubieta-Calleja GR , Zubieta-DeUrioste N , Venkatesh T , Das K , and Soliz J . (2020). COVID-19 and pneumolysis simulating extreme high-altitude exposure with altered oxygen transport physiology; multiple diseases, and scarce need of ventilators: Andean Condor' s-eye-view. Rev Recent Clin Trials [Epub ahead of print]; DOI: 10.2174/1574887115666200925141108.